Skip to main content
OpenTrials
Completed

NCT Number: NCT00225433

Luteal Phase FSH in the IVF Poor Responder

In vitro fertilization (IVF) is a common procedure used to assist couples who have difficulty conceiving a pregnancy. IVF is a process where oocytes (eggs) are retrieved from a woman's ovaries and fertilized with sperm in the laboratory. In order to maximize the number of oocytes that can be retrieved, a women undergoes ovarian stimulation with recombinant follicle stimulating hormone (FSH). Typically 6-20 oocytes are retrieved, but in some cases there is a limited response to the stimulation, producing a limited number of oocytes. This is called poor ovarian response.

This study is designed to objectively compare two treatment regimens currently advocated in clinical practice, but never compared directly. The purpose is to assess ovarian response to starting treatment at the end of the preceding cycle may increase the number of developing oocytes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–42 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

University of Pennsylvania Reproductive Research Unit

Philadelphia, Pennsylvania, 19104, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Infertile women planning to undergo IVF
  • Poor ovarian response in most-recent previous IVF cycle within the past 18 months as defined by the following criteria:

A) <5 dominant follicles day of hCG, B) <5 oocytes retrieved, or C) cancellation of a previous IVF cycle due to poor response to ovulation stimulation.

  • Aged 20-42 (inclusive) at the time of randomization
  • Presence of both ovaries
  • Normal pap smear within past three years
  • At least 45 days after the last IVF cycle
  • Be willing and able to comply with the protocol for the duration of the study
  • Have given written informed consent, prior to any study-related procedure, not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.

Exclusion criteria

  • Clinically significant systemic disease
  • Current regular cigarette smoking by patient report
  • Known to be positive for Human Immunodeficiency Virus
  • Any medical condition which, in the judgment of the investigator and sponsor, may interfere with the absorption, distribution, metabolism or excretion of the medications used
  • Abnormal, undiagnosed gynecological bleeding
  • Known allergy or hypersensitivity to human gonadotropin preparations
  • Simultaneous participation in another investigational drug or device trial
  • Subject fails, in 2 separate menstrual cycle attempts, to have FSH ≤12.0 and an ultrasound exam within normal limits (per standard for IVF) at the Baseline Visit
  • For subjects randomized to the Luteal Phase Regimen, failure to ovulate in 2 separate menstrual cycle attempts, as evidenced by ovulation predictor kit, progesterone level, and /or visualization of corpus luteum cyst on an ovary by ultrasound exam at the Luteal Visit

Treatment and study plan

Follitropin beta

Drug

Follitropin beta

ganirelix acetate

Drug

Ganirelix acetate

Primary outcomes

  1. Number of oocytes retrieved for IVF

    Time frame: One cycle

Secondary outcomes

  1. Number of follicles >10mm on day of human chorionic gonadotropin (hCG) administration;

    Time frame: 1 cycle

  2. Number of days of stimulation;

    Time frame: 1 cycle

  3. Estradiol level on the day of hCG administration;

    Time frame: 1 cycle

  4. Clinical pregnancy rate per transfer: defined as the presence of an intrauterine sac on transvaginal ultrasound;

    Time frame: 1 cycle

  5. Delivery rate per transfer;

    Time frame: 1 cycle

  6. Safety (incidence of ovarian torsion, severe risk of ovarian hyperstimulation syndrome, enlarging hemorrhagic cysts, and serious adverse events)

    Time frame: 1 cycle

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Registry information

Official study title

Luteal Phase Recombinant FSH vs. Follicular Phase Recombinant FSH for IVF Stimulation in the Poor Responder

Important dates

Study start
2005
Primary completion
2006
Study completion
2008
First posted
Sep 23, 2005
Registry last updated
Dec 3, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.